Giant cell tumor of bone overview: Difference between revisions

Jump to navigation Jump to search
 
(9 intermediate revisions by the same user not shown)
Line 16: Line 16:
GCT is characterized by the presence of numerous Cathepsin-K producing, CD33 +, CD14 - multinucleated osteoclast-like giant cells and plump spindle-shaped stromal cells that represent the main proliferating cell population.
GCT is characterized by the presence of numerous Cathepsin-K producing, CD33 +, CD14 - multinucleated osteoclast-like giant cells and plump spindle-shaped stromal cells that represent the main proliferating cell population.
The spindle-shaped mononuclear cells are believed to represent the neoplastic population and are characterized at the cytogenetic level by telomeric associations and a peculiar telomere-protecting capping mechanism.
The spindle-shaped mononuclear cells are believed to represent the neoplastic population and are characterized at the cytogenetic level by telomeric associations and a peculiar telomere-protecting capping mechanism.
Areas of regressive change such as necrosis or fibrosis as well as extensive hemorrhage are frequently present.
Areas of regressive change such as necrosis or fibrosis as well as extensive hemorrhage are frequently present. It recurs from time to time and rates between 25–50% have been reported[2, 6, 15]. In very rare cases, a malignant change may occur.


===Prevalence===
===Prevalence===
Giant cell tumor of the bone accounts for 4-5% of primary bone tumors and 18.2% of benign bone tumors<ref name="pmid12579271">{{cite journal |author=Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS |title=Identification of markers of possible prognostic value in 57 giant cell tumors of bone |journal=[[Oncology Reports]] |volume=10 |issue=2 |pages=351–6 |year=2003 |pmid=12579271 |doi= |url=http://www.spandidos-publications.com/or/10/2/351 |accessdate=2012-01-18}}</ref>.  Giant cell tumors are mostly benign, however 5-10% of patients may have a malignant tumor.


Giant cell tumor of the bone accounts for 4-5% of primary bone tumors and 18.2% of benign bone tumors <ref name="pmid12579271">{{cite journal |author=Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS |title=Identification of markers of possible prognostic value in 57 giant cell tumors of bone |journal=[[Oncology Reports]] |volume=10 |issue=2 |pages=351–6 |year=2003 |pmid=12579271 |doi= |url=http://www.spandidos-publications.com/or/10/2/351 |accessdate=2012-01-18}}</ref>.  Giant cell tumors are mostly benign, however 5-10% of patients may have a malignant tumor.
20% of all benign bone tumours and 5% of all tumours are giant cell tumours. It is more common in young adults between 20 and 40 years of age. It is more common in females with the rate of growth enhanced in pregnancy.  It occurs commonly in the distal femur, the proximal tibia, the distal radius and the sacrum. Giant cell tumors (GCT) usually prefers the epiphyses of long bones. The involvement of the metaphysis or diaphysis without epiphyseal extension is quite uncommon. Often the tumour extends to the articular subchondral bone, However it seldom crosses the joint or its capsule.<ref name="ShrivastavaNawghare2008">{{cite journal|last1=Shrivastava|first1=Sandeep|last2=Nawghare|first2=Shishir P|last3=Kolwadkar|first3=Yogesh|last4=Singh|first4=Pradeep|title=Giant cell tumour in the diaphysis of radius – a report|journal=Cases Journal|volume=1|issue=1|year=2008|pages=106|issn=1757-1626|doi=10.1186/1757-1626-1-106}}</ref>


===Differential Diagnosis===
===Differential Diagnosis===
A number of tumors have giant cells, but are not true benign giant cell tumors. These include
* [[Aneurysmal bone cyst]]
* [[Chondroblastoma]]
* Simple bone cyst
* Osteoid osteoma
* [[Osteoblastoma]]
* [[Osteosarcoma]]
* Giant cell reparative granuloma
* [[Brown tumor]] of hyperparathyroidism.


===History and Symptoms===
===History and Symptoms===
Line 38: Line 30:
* Some patients may be asymptomatic until they develop a pathologic [[fracture]] at the site of the tumor.
* Some patients may be asymptomatic until they develop a pathologic [[fracture]] at the site of the tumor.
===X-Ray===
===X-Ray===
On [[x-ray]], giant cell tumors (GCTs) have a metaepiphyseal location and grow to the articular surface of the involved bone <ref name="pmid11553835">{{cite journal |author=Murphey MD, Nomikos GC, Flemming DJ, Gannon FH, Temple HT, Kransdorf MJ |title=From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation |journal=[[Radiographics : a Review Publication of the Radiological Society of North America, Inc]] |volume=21 |issue=5 |pages=1283–309 |year=2001 |pmid=11553835 |doi= |url=http://radiographics.rsnajnls.org/cgi/pmidlookup?view=long&pmid=11553835 |accessdate=2012-01-18}}</ref>. They are distinguishable from other bony [[tumor]]s in that GCTs usually have a non-sclerotic and sharply defined border. Because giant cell tumors are known to metastasize, when the diagnosis of giant cell tumor is suspected, a chest x-ray or [[computed tomography|CT]] may be needed.
(Images courtesy of RadsWiki)
<div align="left">
<gallery heights="175" widths="175">
Image:Giant-cell-tumor-001.jpg|Giant cell tumor: Distal part of the femur
Image:Giant-cell-tumor-002.jpg|Giant cell tumor: Distal part of the femur
</gallery>
</div>


===MRI===
===MRI===
Line 90: Line 72:
Patients with tumors that are not amenable to [[surgery]] are treated with [[radiation therapy]] <ref name="pmid16462511">{{cite journal |author=Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP |title=Giant cell tumor of bone |journal=[[American Journal of Clinical Oncology]] |volume=29 |issue=1 |pages=96–9 |year=2006 |month=February |pmid=16462511 |doi=10.1097/01.coc.0000195089.11620.b7 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0277-3732&volume=29&issue=1&spage=96 |accessdate=2012-01-18}}</ref>.
Patients with tumors that are not amenable to [[surgery]] are treated with [[radiation therapy]] <ref name="pmid16462511">{{cite journal |author=Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP |title=Giant cell tumor of bone |journal=[[American Journal of Clinical Oncology]] |volume=29 |issue=1 |pages=96–9 |year=2006 |month=February |pmid=16462511 |doi=10.1097/01.coc.0000195089.11620.b7 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0277-3732&volume=29&issue=1&spage=96 |accessdate=2012-01-18}}</ref>.
===Surgery===
===Surgery===
The treatment of choice is intralesional curettage and bone cement packing leading to a local recurrence rate of 10 to 40%. Treatment options are limited and recurrence rates are higher when GCT arises at a surgical inaccessible location (e.g. spine and sacrum).  In addition, some GCT may rarely arise at multiple sites or undergo sarcomatous transformation.<ref name="BalkeNeumann2011">{{cite journal|last1=Balke|first1=Maurice|last2=Neumann|first2=Anna|last3=Szuhai|first3=Károly|last4=Agelopoulos|first4=Konstantin|last5=August|first5=Christian|last6=Gosheger|first6=Georg|last7=Hogendoorn|first7=Pancras CW|last8=Athanasou|first8=Nick|last9=Buerger|first9=Horst|last10=Hagedorn|first10=Martin|title=A short-term in vivo model for giant cell tumor of bone|journal=BMC Cancer|volume=11|issue=1|year=2011|pages=241|issn=1471-2407|doi=10.1186/1471-2407-11-241}}</ref>
The treatment of choice is intralesional curettage and bone cement packing leading to a local recurrence rate of 10 to 40%. Treatment options are limited and recurrence rates are higher when GCT arises at a surgical inaccessible location (e.g. spine and sacrum).  In addition, some GCT may rarely arise at multiple sites or undergo sarcomatous transformation. In about 2% of cases, patients develop lung metastases, which are thought to represent benign pulmonary implants that arise following vascular invasion.<ref name="BalkeNeumann2011">{{cite journal|last1=Balke|first1=Maurice|last2=Neumann|first2=Anna|last3=Szuhai|first3=Károly|last4=Agelopoulos|first4=Konstantin|last5=August|first5=Christian|last6=Gosheger|first6=Georg|last7=Hogendoorn|first7=Pancras CW|last8=Athanasou|first8=Nick|last9=Buerger|first9=Horst|last10=Hagedorn|first10=Martin|title=A short-term in vivo model for giant cell tumor of bone|journal=BMC Cancer|volume=11|issue=1|year=2011|pages=241|issn=1471-2407|doi=10.1186/1471-2407-11-241}}</ref>


* Surgery is the treatment of choice if the [[tumor]] is determined to be resectable.
* Surgery is the treatment of choice if the [[tumor]] is determined to be resectable.

Latest revision as of 20:23, 9 March 2016

Giant cell tumor of bone Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Giant cell tumor of bone from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Giant cell tumor of bone overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Giant cell tumor of bone overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Giant cell tumor of bone overview

CDC on Giant cell tumor of bone overview

Giant cell tumor of bone overview in the news

Blogs on Giant cell tumor of bone overview

Directions to Hospitals Treating Giant cell tumor of bone

Risk calculators and risk factors for Giant cell tumor of bone overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Giant cell tumor of the bone is a relatively uncommon tumor. It is characterized by the presence of multinucleated giant cells (osteoclast-like cells). These tumors are generally benign. In most patients, the tumors are slow to develop, but may recur locally in as many as 50% of cases. Metastasis to the lungs may occur.

Giant cell tumor of the bone is an aggressive skeletal lesion typically located in the epiphyseal end of a long bone.

Epidemiology

The tumor predominantly occurs in the third and fourth decade of life with a slight predilection for females. It is more common in females with the rate of growth enhanced in pregnancy

Pathophysiology

GCT is characterized by the presence of numerous Cathepsin-K producing, CD33 +, CD14 - multinucleated osteoclast-like giant cells and plump spindle-shaped stromal cells that represent the main proliferating cell population. The spindle-shaped mononuclear cells are believed to represent the neoplastic population and are characterized at the cytogenetic level by telomeric associations and a peculiar telomere-protecting capping mechanism. Areas of regressive change such as necrosis or fibrosis as well as extensive hemorrhage are frequently present. It recurs from time to time and rates between 25–50% have been reported[2, 6, 15]. In very rare cases, a malignant change may occur.

Prevalence

Giant cell tumor of the bone accounts for 4-5% of primary bone tumors and 18.2% of benign bone tumors[1]. Giant cell tumors are mostly benign, however 5-10% of patients may have a malignant tumor.

20% of all benign bone tumours and 5% of all tumours are giant cell tumours. It is more common in young adults between 20 and 40 years of age. It is more common in females with the rate of growth enhanced in pregnancy. It occurs commonly in the distal femur, the proximal tibia, the distal radius and the sacrum. Giant cell tumors (GCT) usually prefers the epiphyses of long bones. The involvement of the metaphysis or diaphysis without epiphyseal extension is quite uncommon. Often the tumour extends to the articular subchondral bone, However it seldom crosses the joint or its capsule.[2]

Differential Diagnosis

History and Symptoms

  • Patients usually present with pain and limited range of motion caused by tumor's proximity to the joint space.
  • There may be swelling as well, if the tumor has been growing for a long time.
  • Some patients may be asymptomatic until they develop a pathologic fracture at the site of the tumor.

X-Ray

MRI

MRI can be used to assess intramedullary and soft tissue extension.

(Images courtesy of RadsWiki) Patient #1




Radiation Therapy

Patients with tumors that are not amenable to surgery are treated with radiation therapy [3].

Surgery

The treatment of choice is intralesional curettage and bone cement packing leading to a local recurrence rate of 10 to 40%. Treatment options are limited and recurrence rates are higher when GCT arises at a surgical inaccessible location (e.g. spine and sacrum). In addition, some GCT may rarely arise at multiple sites or undergo sarcomatous transformation. In about 2% of cases, patients develop lung metastases, which are thought to represent benign pulmonary implants that arise following vascular invasion.[4]

  • Surgery is the treatment of choice if the tumor is determined to be resectable.
  • The situation is complicated in a patient with a pathological fracture. It may be best to immobilize the affected limb and wait for the fracture to heal before performing surgery.

References

  1. Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS (2003). "Identification of markers of possible prognostic value in 57 giant cell tumors of bone". Oncology Reports. 10 (2): 351–6. PMID 12579271. Retrieved 2012-01-18.
  2. Shrivastava, Sandeep; Nawghare, Shishir P; Kolwadkar, Yogesh; Singh, Pradeep (2008). "Giant cell tumour in the diaphysis of radius – a report". Cases Journal. 1 (1): 106. doi:10.1186/1757-1626-1-106. ISSN 1757-1626.
  3. Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP (2006). "Giant cell tumor of bone". American Journal of Clinical Oncology. 29 (1): 96–9. doi:10.1097/01.coc.0000195089.11620.b7. PMID 16462511. Retrieved 2012-01-18. Unknown parameter |month= ignored (help)
  4. Balke, Maurice; Neumann, Anna; Szuhai, Károly; Agelopoulos, Konstantin; August, Christian; Gosheger, Georg; Hogendoorn, Pancras CW; Athanasou, Nick; Buerger, Horst; Hagedorn, Martin (2011). "A short-term in vivo model for giant cell tumor of bone". BMC Cancer. 11 (1): 241. doi:10.1186/1471-2407-11-241. ISSN 1471-2407.


Template:WikiDoc Sources